Telehealth for patients with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis protocol

Violeta Gaveikaite, Claudia Fischer, Helen Schonenberg, Steffen Pauws, Spyros Kitsiou, Ioanna Chouvarda, Nicos Maglaveras, Josep Roca

ABSTRACT
Introduction Chronic obstructive pulmonary disease (COPD) is a highly prevalent chronic disease characterised by persistent respiratory symptoms. A focus of COPD interventional studies is directed towards prevention of exacerbations leading to hospital readmissions. Telehealth as a method of remote patient monitoring and care delivery may be implemented to reduce hospital readmissions and improve self-management of disease. Prior reviews have not systematically assessed the efficacies of various telehealth functionalities in patients with COPD at different stages of disease severity. We aim to evaluate which COPD telehealth interventions, classified by their functionalities, are most effective in improving patient outcomes using GRADE.

Methods and analysis We will conduct a systematic review which will include randomised controlled trials comparing the efficacy of telehealth interventions versus standard care in patients with COPD with confirmed disease severity based on forced expiratory volume(%) levels. An electronic search strategy will be used to identify trials published since 2000 in MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, CINHAL. Telehealth is described as remote monitoring and delivery of care where patient data/clinical information is routinely or continuously collected and/or processed, presented to the patient and transferred to a clinical care institution for feedback, triage and intervention by a clinical specialist. Two authors will independently screen articles for inclusion, assess risk of bias and extract data. We will merge studies into a meta-analysis if the interventions, technologies, participants and underlying clinical questions are homogeneous enough. We will use a random-effects model, as we expect some heterogeneity between interventions. In cases where a meta-analysis is not possible, we will synthesise findings narratively. We will assess the quality of the evidence for the main outcomes using GRADE.

Ethics and Dissemination Research ethics approval is not required. The findings will be disseminated through publication in a peer-reviewed journal.

PROSPERO registration number CRD42018083671.

INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a highly prevalent disease that is characterised by persistent respiratory symptoms due to airway and/or alveolar abnormalities caused by significant exposure to noxious particles or gases. COPD results in high societal healthcare expenditures and resource utilisation. The estimated annual economic burden of COPD in terms of conventional direct costs (healthcare utilisation) and indirect costs (lost production) is approximately €141.4 billion in Europe (2011). Where the main costs of COPD are strongly related to disease severity, the other major components of direct costs are hospitalisations (for very severe COPD) and medication (all other severity stages).

Telehealth involves the remote exchange of data between patients and healthcare professionals as part of the patient’s disease status and healthcare management. Telehealth interventions for management of patients
with COPD were introduced more than 20 years ago, but the evidence for the value of telehealth is limited and contradictory. Published systematic reviews on telehealth interventions for the clinical management of patients with COPD only focus on the application of specific services (eg, ‘hospital to home’), specific functions (eg, smart phone intervention) or the experience of clinical professionals (eg, nursing professionals). Even if recent systematic reviews focus on a particular telehealth application or functionality, a lack of established taxonomy in the field greatly limits their value for clinicians. In our systematic review, we propose to look at all telehealth applications and functionalities, as well as to provide a typology for the telehealth interventions of the patients with COPD remote service delivery. This will allow us to describe the use of different telehealth functions across a range of healthcare fields, from health behavioural change interventions to remote patients monitoring such as vital signs observations. This allows us to focus on similarities in mechanisms of action for a particular device or function and to suggest where it might be useful in new remote service selections; all towards the clinical management of patients with COPD. A number of systematic reviews have evaluated the efficacy of telehealth interventions on clinical outcomes in patients diagnosed with COPD. However, the findings vary widely; they are diverse and of poor methodological quality. This may be due to lack of reporting on important patient characteristics, lack of validated data collection instruments and lack of high-quality reporting. However, telehealth interventions are very complex to evaluate because of their dynamic nature; they are designed for a very specific setting; their efficacy is impacted by the behaviour of those delivering who might be resistant to new ICT applications, as well as those receiving the intervention who might fail to comply. This lack of evidence acts as a barrier for further deployment or scaling up of telehealth services.

OBJECTIVES
The aim of this systematic review will be (1) describe how telehealth may be used for the remote management of patients with COPD that have been evaluated in randomised controlled trials (RCTs), (2) derive typology on these telehealth solutions for patients with COPD remote management based on their application for clinical services and specific functionalities and (3) assess the effectiveness of telehealth solutions for improving health and health service outcomes in patients with COPD stratified according to disease severity.

METHODS
The systematic review will be conducted according to the Cochrane Handbook for Systematic Reviews of Interventions and reported according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses for Protocols 2015 methodology.

Eligibility criteria
The Population, Intervention, Comparator and Outcomes components and study design were used to define study selection criteria for eligibility.

Participants
Eligible for inclusion are studies involving patients with a COPD diagnosis based on reported forced expiratory volume in 1 s (FEV1%) (or reported as a Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade). If a reported patient population is mixed, for instance, including patients presenting with asthma, this study will be excluded. Studies that include additional medical conditions as well as COPD will be retained if the outcomes specific to the COPD group are reported separately.

Intervention group: telehealth services
The intervention group is described as patients receiving telehealth as part of a COPD management plan. Telehealth involves the remote exchange of data between a patient and healthcare professionals as part of the patient’s disease status and healthcare management.

The telehealth intervention can involve any IT tool designed for clinical support: an assessment, consultation, triage or intervention performed by the care provider (telemedicine nurse, clinician or service provider, or back-office feedback).

The telehealth component of the management plan may consist of the following functional components: care provider consultations, vital signs monitoring, education/prevention modules, lifestyle coaching. We will exclude studies reporting home mechanical ventilation procedures.

Comparator: standard care
The definition of standard care, if retrievable, will be reported. Standard care is controversial and may vary widely between hospitals and countries; therefore, we include the study if a description of the care has been provided without further restrictions on the type of standard care (care without telehealth component).

Study design
Eligible studies for inclusion are:
► RCTs.
► Cluster RCTs.
► Controlled trials, if they have a randomisation component (feasibility and pilots studies are included).

Search strategy
Electronic databases
Studies will be identified through systematic searches of the following electronic databases: MEDLINE via PubMed, EMBASE, The Cochrane Central Register of Controlled Trials (CENTRAL) and CINAHL. The
preliminary search strategy for CINahl (online supplemental appendix 1) will be adapted for use in the other databases. The Cochrane sensitivity-maximising RCT filter will be applied to MEDLINE and adaptations of it to the other databases except CENTRAL. We will search all databases from 2000 to the present and will impose no restriction on language.

Handsearching literature
We will supplement the main search strategy with manual searches of reference lists of all relevant primary studies and systematic reviews to identify any additional studies not captured by our original search. We will also contact field experts and search the ClinicalTrials.gov Registry for potentially eligible studies.

Reference management
The bibliographic details of all retrieved articles will be stored in Mendeley, a reference management software package. Duplicates will be identified and removed using the Mendeley reference management software.

Study selection and data extraction strategy
Screening and selection of studies
Two authors will independently assess the title and abstract of all identified papers as well as the articles that passed the title and abstract screening based on predefined eligibility criteria. Any disagreements between reviewers will be resolved through discussion or adjudication by a third reviewer. The data extraction form will be adapted to our systematic review and adjusted for optimal data collection through a pilot of several full texts of several included RCTs. Any disagreement arising in the full-text screening stage between reviewers will be resolved through discussion. If agreement cannot be reached, a third reviewer will mediate. All studies that do not fulfill all of the criteria will be excluded and the reasons for their exclusion will be noted. We will identify and collate multiple reports of the same study so that each study is the unit of interest in the review, rather than each report.

Data extraction and management
Data will be independently extracted from the included studies by the first author (VG) and recorded on a predefined extraction form. A second reviewer will check the data for consistency against the published manuscripts to identify any errors. In case of missing data, we will contact the corresponding authors of the included studies where possible. Among other elements, the following data will be captured from studies to be included in the review:

1. Study characteristics: study design, comparator, duration, sample size, setting, country.
2. Participant characteristics: age and sex; FEV%, comorbidities, asthma profile (with/without), smoking status.
3. Intervention characteristics: functionality description (goal, technical details, how service works), how data are collected, how data are reported, adverse events reporting, sustainability of intervention.
4. Feedback criteria: healthcare provider; timing: synchronous or asynchronous; nature: manual or automated.

Valuable qualitative data, such as patient safety will be extracted.

Outcomes: clinical outcomes collection
Six outcomes, commonly reported in COPD clinical trials, were selected to provide relevant information regarding our research question. Studies will be included if at least one of these six outcomes were reported.27

Primary outcomes
Hospital readmissions: COPD-related hospitalisations and hospitalisation causes will be reported. We will differentiate between count and dichotomous data (eg, number of events in each intervention group vs the number of participants in each intervention group who experience at least one event).

Exacerbations: Exacerbation rate is a commonly reported outcome.27 The definition of exacerbations and their severity needs to be standardised to allow comparisons between different interventions in different settings.26 29 As exacerbations can be reported in different ways, the data collection form allows the following to be recorded: number of exacerbations or exacerbation rate (eg, it can be classified based on patient disease severity as well).

- All-cause mortality: Number of patients who died during the study per study group.

Secondary outcomes
Health-related quality of life: disease-specific or non-disease-specific quality of life reported by a validated instrument.

- Physical activity measurements: any type reported by validated measurement.
- COPD-related costs: total and programme related and indirect costs if available.

Risk of bias assessment
Two authors will independently assess risk of bias for each study included in the review using the Cochrane Collaboration Risk of Bias criteria, which assesses the following domains: sequence generation, allocation concealment, blinding of participants and personnel (performance bias), blinding of outcome assessment, whether incomplete outcome data were adequately addressed, and whether there was selective outcome reporting.30

In accordance with the Cochrane risk of bias assessment tool, we will grade each potential source of bias as high, low or unclear and provide a quote from the study report together with a justification for our judgement in the ‘Risk of bias’ table.

Data synthesis
Risk ratios (RRs) will be determined for outcome measures of dichotomous variables. Where possible, RR will be pooled using a random-effects model. The
standard mean difference will be calculated for continuous data variables in the absence of significant clinical heterogeneity. Statistical heterogeneity will be analysed using the I² statistic. To confirm reliability of the summary estimate, 95% CIs will be calculated. If there is important clinical heterogeneity among the included studies, or data are reported using different scales, we will provide a qualitative summary of the findings of the studies by direction of effect and/or statistical significance.

Quality of evidence assessment
A quality of evidence assessment is performed to determine the extent to which we can be confident that an estimate of effect is close to the true quantity/value, that is, it is not distorted by internal or external bias within and across studies. The assessment will be done with the GRADE system. Quality of evidence assessment will be performed by outcome of interest.

Dealing with missing data
Authors will be contacted to obtain unreported data.

Assessment of heterogeneity and reporting biases
We will assess clinical heterogeneity between studies by comparing the characteristics of the study populations, interventions and outcome measures. Statistical heterogeneity will be assessed with the I² and χ² statistic measures. The assessment of reporting biases for the primary outcomes of interest will be explored using funnel plots if we are able to pool more than 10 trials per outcome of interest.

Patients and public involvement
This is a protocol for a systematic review of prior RCTs. Therefore, no human subjects/patients were directly involved in the design and/or execution of this research study. A plain language summary with the main findings of the review will be provided in a straightforward style that can be understood by consumers of healthcare.

DISCUSSION
Overall, the systematic review outlined in this protocol aims to identify, assess and synthesise using meta-analytic methods available in the evidence of the effects of telehealth interventions for the management of patients with COPD. Our systematic review will evaluate which COPD telehealth interventions, classified by their functionalities, are most effective in improving patient with COPD management measured by both clinical and resource utilisation outcomes. It will allow better clinical service selection, which aims to tailor the telehealth services to the specific COPD severity and patient needs. Based on published RCTs, it will describe the telehealth solutions usability and efficacy in terms of clinical outcomes and service utilisation for the patients with COPD remote management. Clinical outcomes reporting will be focused on the patient profile (comorbidities, FEV% and no asthma cases) which strengthens this systematic review and facilitates the evidence implementation in a future individual patient service selection procedure. Heterogeneous reporting in trials on telehealth, and the limited number of trials for some of the interventions, which are foreseen based on a scoping search, may limit our ability to draw conclusions on telehealth efficacy following the meta-analysis. The gathered information will help to derive the typology of telehealth solutions for patients with COPD remote management based on their application for the clinical services and specific functionalities.

REFERENCES
1. Global Initiative for Chronic Obstructive Lung Disease. Pocket Guide to Copd Diagnosis, Management, and Prevention a Guide for Health Care Professionals. 2017.
2. Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health 2015;5:020415.
3. Teo WS, Tan WS, Chong WF, et al. Economic burden of chronic obstructive pulmonary disease. Respirology 2012;17:120–6.
4. Kauczor HU, Bonomo L, Gaga M, et al. ESR/ERS white paper on lung cancer screening. Eur Radiol 2015;25:2519–31.
5. Jansson SA, Backman H, Sterling A, et al. Health economic costs of COPD in Sweden by disease severity–has it changed during a ten years period? Respir Med 2013;107:1931–8.
6. McLean S, Protti D, Sheikh A. Telehealthcare for long term conditions. *BMJ* 2011;342:d120.

7. Sood S, Mbarika V, Jugoo S, et al. What is telemedicine? A collection of 104 peer-reviewed perspectives and theoretical underpinnings. *Teledmed J E Health* 2007;13:573–90.

8. Wootten R. Twenty years of telemedicine in chronic disease management—an evidence synthesis. *J Teledmed Telecare* 2012;18:211–20.

9. Jeppesen E, Brurberg KG, Vist GE, et al. Hospital at home for acute exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2012;55.

10. Ram FS, Wedzicha JA, Wright J, et al. Hospital at home for patients with acute exacerbations of chronic obstructive pulmonary disease: systematic review of evidence. *BMJ* 2004;329:315.

11. Alwashmi M, Hawboldt J, Davis E, et al. The effect of smartphone interventions on patients with chronic obstructive pulmonary disease exacerbations: a systematic review and meta-analysis. *JMIR Mhealth Uhealth* 2016;4:e105.

12. Kamei T, Yamamoto Y, Kajii F, et al. Systematic review and meta-analysis of studies involving telehome monitoring-based telenursing for patients with chronic obstructive pulmonary disease. *Japan J Nurs Sci* 2013;10:180–92.

13. Hersch RK, Cook RF, Delitz DK, et al. Reducing nurses’ stress: A randomized controlled trial of a web-based stress management program for nurses. *Appl Nurs Res* 2016;32:18–25.

14. Polisena J, Tran K, Cimon K, et al. Home telehealth for chronic obstructive pulmonary disease: a systematic review and meta-analysis. *J Teledmed Telecare* 2010;16:120–7.

15. Lundell S, Holmner Å, Rehn B, et al. Telehealthcare in COPD: a systematic review and meta-analysis on physical outcomes and dyspnea. *Respir Med* 2015;109:11–26.

16. McLean S, Nurmatov U, Liu JL, et al. Telehealthcare for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2011;7:CD007718.

17. Pedone C, Lelli D. Systematic review of telemonitoring in COPD: an update. *Pneumonol Alergol Pol* 2015;83:476–84.

18. Kitsiou S, Paré G, Jaana M. Systematic reviews and meta-analyses of home telemonitoring interventions for patients with chronic diseases: a critical assessment of their methodological quality. *J Med Internet Res* 2013;15:e150.

19. Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating complex interventions: the new Medical Research Council guidance. *BMJ* 2008;337:a1655–983.

20. Tacconelli E. Systematic reviews: CRD’s guidance for undertaking reviews in health care. *Lancet Infect Dis* 2010;10:226.

21. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;350:g7647.

22. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1.

23. Barnes PJ. Mechanisms in COPD: differences from asthma. *Chest* 2000;117:10S–14.

24. Cruz J, Brooks D, Marques A. Home telemonitoring in COPD: a systematic review of methodologies and patients’ adherence. *Int J Med Inform* 2014;83:249–63.

25. Whitehead AL, Sully BG, Campbell MJ. Pilot and feasibility studies: is there a difference from each other and from a randomised controlled trial? *Contemp Clin Trials* 2014;38:130–3.

26. Cochrane Public Health Group, 2011. Data extraction and assessment template. http://ph.cochrane.org/review-authors

27. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. *Eur Respir J* 2008;31:416–69.

28. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. *Ann Intern Med* 1987;106:196.

29. Gov.UK. An outcomes strategy for copd and asthma: nhs companion document. 2012.

30. Higgins JPT, Chapter AD. Assessing Risk of Bias in Included Studies Cochrane Handbook for Systematic Reviews of Interventions. 5.0.1, 2008.

31. Ioannidis JP, Patsopoulos NA, Rothstein HR. Reasons or excuses for avoiding meta-analysis in forest plots. *BMJ* 2008;336:1413–5.

32. Ioannidis JP, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. *BMJ* 2007;335:914–6.

33. Ross S, Curry N, Goodwin N. “Case management: What it is and how it can best be implemented: The King’s Fund Paper, 2011."